Open AccessThis article is
- freely available
Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis
Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY 14214, USA
* Authors to whom correspondence should be addressed.
Received: 23 March 2010; in revised form: 13 April 2010 / Accepted: 26 April 2010 / Published: 28 April 2010
Abstract: In spite of its public health importance, our understanding of the mechanisms of breast carcinogenesis and progress is still evolving. The metabolic syndrome (MS) is a constellation of biochemical abnormalities including visceral adiposity, hyperglycemia, hyperinsulinemia, dyslipidemia and high blood pressure. The components of the MS have all been related to late-stage disease and even to a poor prognosis of breast cancer through multiple interacting mechanisms. In this review, we aim to present a summary of recent advances in the understanding of the contribution of the MS to breast cancer with the emphasis on the role of biomarkers of the MS in the prognosis of breast cancer.
Keywords: metabolic syndrome; breast cancer; epidemiology; biomarkers; prognosis
Citations to this Article
Cite This Article
MDPI and ACS Style
Zhu, Q.-L.; Xu, W.-H.; Tao, M.-H. Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis. Cancers 2010, 2, 721-739.
Zhu Q-L, Xu W-H, Tao M-H. Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis. Cancers. 2010; 2(2):721-739.
Zhu, Qiu-Li; Xu, Wang-Hong; Tao, Meng-Hua. 2010. "Biomarkers of the Metabolic Syndrome and Breast Cancer Prognosis." Cancers 2, no. 2: 721-739.